None listed
Conditions
Interventions
Dietary Supplement : Subjects will be randomized to receive BST898 510mg or placebo. Subjects will orally self-adminster BST898 or placebo bid, 2Tab per day for 12weeks.
Sponsors
Biostream Technologies
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial. 2) Male and female subjects between 20-60years of age inclusive 3)BMI of 25.0-29.9kg/m2
Exclusion criteria
Exclusion criteria: 1)The Patients with severe cerebrovascular disease, cardiac disease (If that patient's clinical status is stable, they can participate in the clinical trial according to investgator) 2)Subjects with systolicBP = 160 mmHg or diastolicBP = 100 mmHg and also taking a beta blocker or a hydragogue. 3)Subjects with diabetes(use of hypoglycemic agent or insulin)or fasting blood glucose = 126 mg/dL or random blood glucose = 200 mg/dL. 4)TSH(Thyroid Stimulating Hormone) value =0.1uU/ml or =10 uU/ml 5)Serum creatinine = 2 times the upper limit of normal. 6)Serum AST(Aspartate aminotransferase)/ALT(Alanine aminotransferase) = 3 times the upper limit of normal. 7)Subjects who complain gastrointestinal symptoms such as heartburn, dyspepsia 8)The patient who take the medicine that can affect the state of weight change (uptake inhibitors, appetite suppressant, Antipsychotics hydragogue, contraceptives, steroid, and female sex hormon) within recent 1 months. 9)Participation in commercial diet program within the 3 months prior to screening. 10)Participation in any clinical trail within the 1 month prior to screening or have a plan to participate in other clinical trial. 11)Subjects who get hospitalization, medications or rehabilitation treatments for Alcohol disorders, cardiovascular disease, disorder of central nervous system. 12)Subjects with the musculoskeletal disorders or restricted physical activity. 13)Woman who are pregnant of lactating or planning to pregnant 14)Subjects which in the opinion investigator could affect preclude evluation of response
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Body weight , Body mass index(BMI) ;Waist circumference, Hip circumference, waist-hip ratio(WHR) ;Fat mass, Fat Free Mass(by Dual Energy X-Ray Absorptiometry, DEXA) ;Mesenteric fat area, Subcutaneous fat area, Total abdominal fat area, Mesenteric fat area/Subcutaneous fat area(by CT) ;Blood Lipid ;Adiponectin, Leptin, hs-CRP( high-sensitivity C-reactive protein) | — |
Primary
| Measure | Time frame |
|---|---|
| Chainge in fat percentage(by Dual Energy X-Ray Absorptiometry, DEXA) | — |
Countries
Korea, Republic of
Contacts
Public ContactJae Kang
Inje University Seoul Paik Hospital
Outcome results
None listed